Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Ucb SA

UCB:BRU

Ucb SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)126.70
  • Today's Change2.00 / 1.60%
  • Shares traded159.69k
  • 1 Year change+43.52%
  • Beta0.5850
Data delayed at least 15 minutes, as of May 20 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 16-May-24
Select bar for recommendation details.
Recommendations16-May-24
Buy4
Outperform12
Hold5
Underperform1
Sell0

Share price forecast in EUR

The 19 analysts offering 12 month price targets for UCB SA have a median target of 130.00, with a high estimate of 166.00 and a low estimate of 105.00. The median estimate represents a 4.25% increase from the last price of 124.70.
High33.1%166.00
Med4.3%130.00
Low-15.8%105.00

Dividends in EUR

In 2023, Ucb SA reported a dividend of 0.95 EUR, which represents a 2.26% increase over last year. The 17 analysts covering the company expect dividends of 1.42 EUR for the upcoming fiscal year, an increase of 48.74%.
Div growth (TTM)2.26%
More ▼

Earnings history & estimates in EUR

UCB SA reported annual 2023 earnings of 4.20 per share on Feb 28, 2024.
Average growth rate-3.10%
More ▼

Revenue history & estimates in EUR

UCB SA had revenues for the full year 2023 of 5.25bn. This was 4.80% below the prior year's results.
Average growth rate+1.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.